Equillium, Inc. — Director's Dealing 2021

Feb 16, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Equillium, Inc. (EQ)
CIK: 0001746466
Period of Report: 2021-02-05

Reporting Person: Decheng Capital Global Life Sciences Fund IV, L.P. (10% Owner)
Reporting Person: Decheng Capital Management IV (Cayman), LLC (10% Owner)
Reporting Person: Cui Xiangmin (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3285710	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrant (right to buy)	$14.00	2026-02-05	Common Stock (985713)		Indirect

Footnotes

F1: The reportable securities are included within 3,285,710 units representing (i) 3,285,710 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), and (ii) warrants to purchase an additional 985,713 shares of Common Stock for $7.00 per unit (each unit consisting of one share of Common Stock and a warrant to purchase 0.3 of a share of Common Stock).

F2: The reportable securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. (the "Fund"). Decheng Capital Management IV (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.